Research & Policy Context
Orderly’s pages clearly state that compounded GLP‑1s are not evaluated or approved by the FDA, while Wegovy and Zepbound are FDA‑approved.
In late 2024 and early 2025, FDA declared the tirzepatide and semaglutide shortages resolved, reducing the flexibility pharmacies had to compound these products. Enforcement and state policies continue to evolve.
In April 2025, Orderly published a response to an Eli Lilly cease‑and‑desist letter related to compounded tirzepatide, underscoring scrutiny of GLP‑1 compounding.
Terms list multiple partner pharmacies and note that not all prescriptions are dispensed in child‑resistant containers. Cancellations are allowed only before a provider finalizes the prescription; full refunds apply if you are not approved.
- Compounded GLP‑1s are not FDA‑approved
- FDA shortages resolved: tirzepatide (Dec 2024), semaglutide (Feb 2025)
- Orderly response to Lilly C&D (Apr 2025)
- No expedited shipping; typical delivery 8–10 business days






